Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06828055 · ClinicalTrials.gov registry record · Phase 2
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
A Phase 2 study of Weight Loss, sponsored by Viking Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 15
- Study locations
NCT06828055: Completed Phase 2 study of Weight Loss, sponsored by Viking Therapeutics.
NCT06828055 is a Phase 2 study of Weight Loss that has completed, run by Viking Therapeutics. The registered enrollment target is 280 participants, below the 1,499-participant average among 116 other Weight Loss trials with a reported enrollment target (81% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06828055, a Phase 2 study of Weight Loss, has completed, sponsored by Viking Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Primary Outcome
To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VK2735
Study Locations (15)
Florida
- Viking Clinical Site #101 - Clearwater
- Viking Clinical Site #108 - Largo
- Viking Clinical Site #107 - Ocoee
- Viking Clinical Site #102 - Port Orange
Missouri
- Viking Clinical Site #109 - City of Saint Peters
- Viking Clinical Site #112 - Kansas City
Texas
- Viking Clinical Site #104 - Austin
- Viking Clinical Site #106 - San Antonio
Arizona
- Viking Clinical Site #111 - Peoria
California
- Viking Clinical Site #105 - Lake Forest
Indiana
- Viking Clinical Site #100 - Indianapolis
Kentucky
- Viking Clinical Site #110 - Louisville
Louisiana
- Viking Clinical Site #114 - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2025-08-15 |
| Phase | Phase 2 |
What the finished NCT06828055 record still lists
NCT06828055 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 1,499-participant average among 116 other Weight Loss trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06828055 lists 15 locations in 10 states (Florida, Missouri, Texas).
Frequently Asked Questions
What is clinical trial NCT06828055 about?
NCT06828055 is a clinical study titled "VK2735 for Weight Management Phase 2 (Venture Oral Dosing)". This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are over...
What is the current status of trial NCT06828055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2024-12-18. Estimated completion is 2025-08-15.
What conditions does trial NCT06828055 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT06828055?
The interventions under investigation include: Placebo (DRUG), VK2735 (DRUG).
Who is sponsoring clinical trial NCT06828055?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06828055 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06828055's enrollment target sits among peer trials
280 21st of 116 higher than 96 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fasted vs. Fed State Exercise
RECRUITING · Phase 2
-
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
RECRUITING · Phase 2
-
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
RECRUITING · Phase 2
-
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
RECRUITING · Phase 2
-
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI